Showing results (91-100 of 237) with videos related to
Sort By:
Pageof 24
American Journal of Hematology|June 15, 2017
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSandra Eder, Jonathan Canaani, Eric Beohou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study GroupJohannes Schetelig, Martin Bornhäuser, Christoph Schmid, et al.Bone Marrow Transplantation|March 6, 2019
The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's LymphomaTobias A W Holderried, Alessia Fraccaroli, Martin Schumacher, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, et al.Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.Hemasphere|March 21, 2024
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort studyPhilipp Berning, Evgenii Shumilov, Markus Maulhardt, et al.Blood|April 9, 2005
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Michael Stadler, et al.British Journal of Haematology|April 10, 2021
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemiaMohamed A Kharfan-Dabaja, Myriam Labopin, Eolia Brissot, et al.Leukemia|June 25, 2024
How risky is a second allogeneic stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.Pageof 24